CloudMD Software & Services Inc.

Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2021 and 2020

(Unaudited)

(Expressed in thousands of Canadian dollars, except number of shares and per share amounts)

Condensed Interim Consolidated Statements of Financial Position (Expressed in thousands of Canadian Dollars) (Unaudited)

	Note	Sep	tember 30, 2021	December 2020	31,
ASSETS					
Current assets					
Cash and cash equivalents	14	\$	53,685	\$	59,714
Trade and other receivables			22,261		2,012
Inventory			3,405		729
Prepaid expenses, deposits and other			3,132		758
Net investment in sublease			59		154
Total current assets			82,542		63,367
Deposits			238		238
Net investment in sublease			-		20
Deferred tax assets			2,198		_
Investment in joint venture	4		319		-
Property and equipment	7		12,235		5,792
Intangible assets	8		11,814		8,184
Goodwill	8		205,183		44,259
Total assets		\$	314,529	\$	121,860
LIABILITIES AND SHAREHOLDERS' EQUITY					
Current liabilities					
Accounts payable, accrued liabilities and other		\$	27,535	\$	3,453
Deferred revenue			1,589		888
Contingent consideration	10		14,919		136
Contingent liability	18		1,350		1,350
Current portion of lease liabilities	11		2,139		1,170
Current portion of long-term debt	9		2,408		619
Total current liabilities			49,940		7,616
Contingent consideration	10		18,474		1,194
Lease liabilities	11		7,189		3,494
Long-term debt	9		22,582		2,027
Total liabilities			98,185		14,331
SHAREHOLDERS' EQUITY					
Share capital	13		227,560		112,351
Reserves			11,923		7,277
Shares under escrow			2,562		1,061
Contingent shares issuable			9,813		6,172
Accumulated other comprehensive loss			(74)		(2)
Deficit			(36,299)	(20,174)
Equity attributable to equity holders of the parent			215,485		106,685
Non-controlling interest			859		844
Total shareholders' equity			216,344		107,529
Total liabilities and shareholders' equity		\$	314,529	\$	121,860

Subsequent event (Note 19)

Approved and authorized for issuance by the Board of Directors on November 29, 2021.

"Essam Hamza"	"Christopher Cherry"
Essam Hamza, Director	Christopher Cherry, Director

Condensed Interim Consolidated Statements of Net Loss and Comprehensive Loss (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

Note 2021 2020 2021 2020 2021 2020 2021 2020 2020 2021 2020			_	Three me	ont	hs ended	_	Nine months ended		ended
Revenue		Note		•		•		•		September 30, 2020
Cost os sales		11010								
Expenses Sales and marketing 2,530 769 5,453 2	Revenue	5	\$	39,162	\$	3,359	\$	63,596	\$	9,205
Sales and marketing	Cost of sales			25,866		2,100		41,152		5,792
Sales and marketing 2,530 769 5,453 2 Research and development 1,196 394 2,921 1 General and administrative 8,984 1,499 15,907 3 Share-based compensation 13 1,543 559 4,576 1 Amortization of intangible assets 8 307 63 758 1 Pepreciation of property and equipment 7 776 199 1,843 1 Financing-related costs - 245 871 1 2 171 360 1 1 2 171 360 1 37,803 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 3 1 3 1 1 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1 3 1	Gross profit			13,296		1,259		22,444		3,413
Research and development	Expenses									
General and administrative	Sales and marketing			2,530		769		5,453		2,285
Share-based compensation 13 1,543 5.59 4,576 1. Amortization of intangible assets 8 307 63 758 Depreciation of property and equipment 7 776 199 1,843 Financing-related costs - 245 871 Acquisition-related and integration costs 1,802 190 5,474 Total expenses 17,138 3,918 37,803 10 Loss before undernoted (3,842) (2,659) (15,359) (6 Other income 102 17 360 Change in fair value of contingent consideration 10 640 - 966 Change in fair value of contingent consideration 10 640 - 966 Contingent liability expense 18 Contingent liability expense 18 Finance costs (774) (63) (974) (63) Other costs (3,874) (2,705) (15,007) (7,000 Deferred tax expense (302) - (302) Income tax expense (143) (19) (298) Net loss for the period (4,319) (2,724) (15,607) (7,000 Other comprehensive loss 16 (4,229) (2,724) (15,679) (7,000 Total comprehensive loss for the period (4,327) (2,724) (15,679) (7,000 (7,00	Research and development			1,196		394		2,921		1,154
Amortization of intangible assets 8 307 63 758 Depreciation of property and equipment 7 776 199 1,843 Financing-related costs 2 245 871 Acquisition-related and integration costs 1,802 190 5,474 Total expenses 17,138 3,918 37,803 10 Loss before undernoted (3,842) (2,659) (15,359) (6 Other income	General and administrative			8,984		1,499		15,907		3,566
Depreciation of property and equipment 7 776 199 1,843 Financing-related costs - 245 871 Acquisition-related and integration costs 1,802 190 5,474 Total expenses 17,138 3,918 37,803 100	Share-based compensation	13		1,543		559		4,576		1,508
Financing-related costs	Amortization of intangible assets	8		307		63		758		186
Acquisition-related and integration costs 1,802 190 5,474 Total expenses 17,138 3,918 37,803 10 Loss before undernoted (3,842) (2,659) (15,359) (6 Other income 102 17 360 Change in fair value of contingent consideration 10 640 - 966 Contingent liability expense 18 - - (6 Contingent liability expense 18 - - - (6 Finance costs (774) (63) (974) (63) Finance costs (3,874) (2,705) (15,007) (7 Other costs (3,874) (2,705) (15,007) (7 Other dax expense (302) - (302) Income tax expense (302) - (302) Income tax expense (4,319) (2,724) (15,607) (7 Other comprehensive loss for the period (4,319) (2,724) (15,607) (7 Other comprehensive loss for the period (4,229) (2,724) (15,607) (7 Other comprehensive loss for the period (4,229) (2,724) (15,607) (7 Total comprehensive loss for the period (4,237) (2,724) (15,622) (7 Non-controlling interest 8 - 15 Total comprehensive loss attributable to: Equity holders of the Company (4,237) (2,724) (15,694) (7 Non-controlling interest 8 - 15 Total comprehensive loss attributable to: Equity holders of the Company (4,237) (2,724) (15,694) (7 Non-controlling interest 8 - 15 Total comprehensive loss attributable to: Equity holders of the Company (4,237) (2,724) (15,694) (7 Non-controlling interest 8 - 15	Depreciation of property and equipment	7		776		199		1,843		487
Total expenses	Financing-related costs			-		245		871		505
Content Cont	Acquisition-related and integration costs			1,802		190		5,474		310
Other income Change in fair value of contingent consideration 10 640 - 966 Contingent liability expense 18 (774) (63) (974) (63) Ret loss before taxes (774) (63) (2705) (15,007) (700) Contended tax expense (302) - (302) Contingent liability expense (303) - (302) Contingent liability expense (302) - (302) Contingent liability expense (32) (46) 352 Contingent liability expense (32) (46) 352 Contingent liability expense (4,319) (2,724) (15,007) Control of the company solution of foreign operations Control of the Company solution liability expense Contingent liability liability Contingent liability Contingent liability Contingent liability liability Conting	Total expenses			17,138		3,918		37,803		10,001
Change in fair value of contingent consideration 10	Loss before undernoted			(3,842)		(2,659)		(15,359)		(6,588)
Contingent liability expense 18	Other income			102		17		360		82
Contingent liability expense 18	Change in fair value of contingent consideration	10		640		-		966		-
Finance costs (774) (63) (974) (63) (974) (63) (974) (63) (974) (63) (974) (63) (974) (63) (974) (63) (974) (63) (974) (63) (974) (9	•	18		-		-		-		(400)
Net loss before taxes (3,874) (2,705) (15,007) (7)	Finance costs			(774)		(63)		(974)		(190)
Deferred tax expense (302) - (302)								. ,		(508)
Deferred tax expense (302) - (302)	Net loss before taxes			(3.874)		(2.705)		(15,007)		(7,096)
Income tax expense (143) (19) (298) Net loss for the period (4,319) (2,724) (15,607) (7, 17) Other comprehensive loss Item that may be reclassified to income in subsequent periods Exchange differences on translation of foreign operations 90 - (72) Total comprehensive loss for the period (4,229) \$ (2,724) \$ (15,679) \$ (7, 17) Net loss attributable to: Equity holders of the Company \$ (4,327) \$ (2,724) \$ (15,622) \$ (7, 18) Non-controlling interest 8 - 15 Total comprehensive loss attributable to: Equity holders of the Company \$ (4,237) \$ (2,724) \$ (15,694) \$ (7, 18) Non-controlling interest 8 - 15 Weighted average number of common shares, basic and diluted 232,085,178 116,363,565 203,989,994 100,420,						(=,, ==)				-
Net loss for the period (4,319) (2,724) (15,607) (7.00) Other comprehensive loss Item that may be reclassified to income in subsequent periods 90 - (72) Exchange differences on translation of foreign operations 90 - (72) Total comprehensive loss for the period \$ (4,229) \$ (2,724) \$ (15,679) \$ (7.00) Net loss attributable to: Equity holders of the Company \$ (4,327) \$ (2,724) \$ (15,622) \$ (7.00) Non-controlling interest 8 - 15 Total comprehensive loss attributable to: Equity holders of the Company \$ (4,237) \$ (2,724) \$ (15,694) \$ (7.00) Non-controlling interest 8 - 15 Weighted average number of common shares, basic and diluted 232,085,178 116,363,565 203,989,994 100,420.00	*					(19)				(19)
Exchange differences on translation of foreign operations 90	Net loss for the period			, ,				. ,		(7,115)
Exchange differences on translation of foreign operations 90 - (72) Total comprehensive loss for the period \$ (4,229) \$ (2,724) \$ (15,679) \$ (7) Net loss attributable to: Equity holders of the Company \$ (4,327) \$ (2,724) \$ (15,622) \$ (7) Non-controlling interest 8 - 15 Total comprehensive loss attributable to: Equity holders of the Company \$ (4,237) \$ (2,724) \$ (15,694) \$ (7) Non-controlling interest 8 - 15 Weighted average number of common shares, basic and diluted 232,085,178 116,363,565 203,989,994 100,420	Other comprehensive loss									
Exchange differences on translation of foreign operations 90 - (72) Total comprehensive loss for the period \$ (4,229) \$ (2,724) \$ (15,679) \$ (7) Net loss attributable to: Equity holders of the Company \$ (4,327) \$ (2,724) \$ (15,622) \$ (7) Non-controlling interest 8 - 15 Total comprehensive loss attributable to: Equity holders of the Company \$ (4,237) \$ (2,724) \$ (15,694) \$ (7) Non-controlling interest 8 - 15 Weighted average number of common shares, basic and diluted 232,085,178 116,363,565 203,989,994 100,420	Item that may be reclassified to income in subsequent periods									
Net loss attributable to: Equity holders of the Company \$ (4,327) \$ (2,724) \$ (15,622) \$ (7.502	Exchange differences on translation of foreign operations			90		-		(72)		-
Equity holders of the Company \$ (4,327) \$ (2,724) \$ (15,622) \$ (7,724) \$ Non-controlling interest \$ 8 \$ - \$ 15 \$ (7,724) \$ (15,622) \$ (7,724) \$ (15,624) \$ (7,724) \$ (15,694) \$ (7,724) \$ Non-controlling interest \$ 8 \$ - \$ 15 \$ (7,724) \$ (15,694) \$ (7,724) \$ Non-controlling interest \$ 8 \$ - \$ 15 \$ (7,724) \$ (15,694) \$ (15,694) \$ (15,69	Total comprehensive loss for the period		\$	(4,229)	\$	(2,724)	\$	(15,679)	\$	(7,115)
Equity holders of the Company \$ (4,327) \$ (2,724) \$ (15,622) \$ (7,724) \$ Non-controlling interest \$ 8 \$ - \$ 15 \$ (7,724) \$ (15,622) \$ (7,724) \$ (15,624) \$ (7,724) \$ (15,694) \$ (7,724) \$ Non-controlling interest \$ 8 \$ - \$ 15 \$ (7,724) \$ (15,694) \$ (7,724) \$ Non-controlling interest \$ 8 \$ - \$ 15 \$ (7,724) \$ (15,694) \$ (15,694) \$ (15,69	Nat loss attributable to:									
Non-controlling interest 8 - 15 Total comprehensive loss attributable to: Equity holders of the Company \$ (4,237) \$ (2,724) \$ (15,694) \$ (7,724) \$ (7,724) \$ (15,694) \$ (7,724) Non-controlling interest 8 - 15 Weighted average number of common shares, basic and diluted 232,085,178 116,363,565 203,989,994 100,420,633,633,633,633,633,633,633,633,633,63			¢	(4 327)	\$	(2.724)	¢	(15.622)	\$	(7,115)
Equity holders of the Company \$ (4,237) \$ (2,724) \$ (15,694) \$ (7.000) \$ Non-controlling interest 8 - 15 \$ (7.000) \$ Weighted average number of common shares, basic and diluted \$ 232,085,178 \$ 116,363,565 \$ 203,989,994 \$ 100,420.	* *		φ		Ψ	-	Ψ		Ψ	- (7,113)
Equity holders of the Company \$ (4,237) \$ (2,724) \$ (15,694) \$ (7.000) \$ Non-controlling interest 8 - 15 \$ (7.000) \$ Weighted average number of common shares, basic and diluted \$ 232,085,178 \$ 116,363,565 \$ 203,989,994 \$ 100,420.	Total comprehensive loss attributable to:									
Non-controlling interest 8 - 15 Weighted average number of common shares, basic and diluted 232,085,178 116,363,565 203,989,994 100,420,	•		\$	(4.237)	\$	(2.724)	\$	(15.694)	\$	(7,115
	1 7		Ψ	` ' '	Ψ	-	Ψ	` / /	4	-
	Weighted average number of common shares, basic and diluted			232,085,178		116,363,565		203,989,994		100,420,694
Ecos per share, basic and unucle φ (0.02) φ (0.02) φ (0.05) φ (0.06)	Loss per share, basic and diluted		\$	(0.02)	\$	(0.02)	\$	(0.08)	\$	(0.07)

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Expressed in thousands of Canadian Dollars) (Unaudited)

	Share capital	Reserves	Shares under escrow	Contingent shares issuable	Accumulated other comprehensive loss	Deficit	Non-controlling interest	7	Γotal
Balance, December 31, 2019	\$ 16,792 \$	2,285	-	\$ -	\$ - \$	(7,835)	\$	· \$	11,242
Shares issued for business combinations	1,043	-	-	-	-	-		-	1,043
Private placements	3,023	-	-	-	=	-		-	3,023
Bought deal financing	35,740	-	-	-	-	-		-	35,740
Share issuance costs	(5,382)	1,969	-	-	-	-		-	(3,413)
Exercise of stock options	1,440	(623)	-	-	-	-		-	817
Exercise of warrants	3,393	(389)	-	-	-	-		-	3,004
Shares issued for settlement of debt	578	-	-	-	-	_		-	578
Shares issued for services	409	-	-	-	-	_		-	409
Share-based compensation	-	1,508	-	-	-	-		-	1,508
Other comprehensive loss	-	-	-	-	-	-		-	-
Net loss for the period	-	-	-	-	-	(7,115)		-	(7,115)
Balance, September 30, 2020	\$ 57,036 \$	4,750	-	\$ -	\$ - \$	(14,950)	\$	- \$	46,836
Balance, December 31, 2020	\$ 112,351 \$	7,277	1,061	\$ 6,172	\$ (2) \$	(20,174)	\$ 844	\$	107,529
Shares issued/issuable for business combinations	51,916	-	1,501	4,409	-	-		-	57,826
Shares issued for investment in joint venture	129	-	-	-	-	-		-	129
Shares issued/issuable for asset purchase	1,108	-	-	190	-	_		-	1,298
Bought deal financing	58,212	-	-	-	-	_		-	58,212
Contingent shares issued	1,461	-	_	(958)	-	(503)		-	-
Share issuance costs	(5,749)	1,528	-	-	-	_		-	(4,221)
Exercise of stock options	2,040	(773)	_	-	-	-		-	1,267
Exercise of restricted share units	470	(470)	-	-	-	-		-	-
Exercise of warrants	3,167	(1)	-	-	-	_		-	3,166
Shares issued for services	2,455	-	-	-	-	_		-	2,455
Share-based compensation	-	4,362	_	-	-	-		-	4,362
Other comprehensive loss	-	- -	_	-	(72)	-		-	(72)
Net loss for the period	-	-	_	-	-	(15,622)	15	i	(15,607)
Balance, September 30, 2021	\$ 227,560 \$	11,923	2,562	\$ 9,813	\$ (74) \$		\$ 859		216,344

Condensed Interim Consolidated Statements of Cash Flows (Expressed in thousands of Canadian Dollars) (Unaudited)

		Three mo	nth	s ended	Nine mo	Nine months ende	
	_	mber 30, 021		September 30, 2020	September 30, 2021		September 30, 2020
Operating activities							
Net loss for the period	\$	(4,319)	\$	(2,724) \$	(15,607)	\$	(7,115
Adjustments for	·	() /			(, , , ,		
Interest expense on lease liabilities		87		38	211		98
Accretion expense on contingent consideration		283		_	307		
Interest expense on long term debt		406		25	457		9
Deferred tax expense		302		_	302		
Amortization of intangible assets		307		63	758		18
Depreciation of property and equipment		776		199	1,843		48
Share-based compensation		1,543		559	4,576		1,50
Shares issued for services		_,		_	2,455		13:
Gain on debt forgiveness		_		(20)	-		(135
Contingent liability expense		_			_		40
Unrealized foreign exchange loss (gain)		51		_	(1)		
Share in profits of joint venture		(7)		_	(9)		
Interest income from net investment in sublease		(1)		(2)	(4)		(2
Change in fair value of contingent consideration		(640)		(-) -	(966)		(-
Net change in non-cash working capital		(4,216)		146	(5,020)		6
Net cash used in operating activities		(5,428)		(1,716)	(10,698)		(4,282
Acquisition of businesses, net of cash acquired Investment in joint venture Short-term investments		(242)		(267) - (100)	(72,293) (181)		(326
Payments received from net investment in sublease		40		(100)	119		(123
Purchase of intangible assets				(5)			(10
Purchase of property and equipment		(263)		(32)	(744) (537)		(116
Net cash used in investing activities		(318)		(378)	(73,636)		(551
Net cash used in investing activities		(703)		(378)	(73,030)		(331
Financing activities							
Shares issued for cash		-		20,789	58,212		38,76
Share issuance costs				(1,691)	(4,221)		(3,413
Proceeds from exercise of stock options		355		2,820	1,267		3,00
Proceeds from exercise of warrants		262		742	3,166		82:
Proceeds from long-term debt, net of financing costs		-		-	23,633		
Payment of long-term debt		(1,057)		(263)	(2,153)		(581
Payment of lease liabilities		(584)		(214)	(1,527)		(474
Payment of line of credit		-		74	(2)		(1,030
Net cash (used in) provided by financing activities		(1,024)		22,257	78,375		37,08
Net (decrease) increase in cash and cash equivalents		(7,235)		20,163	(5,959)		32,25
Cash and cash equivalents, beginning of period		60,880		13,787	59,714		1,696
Foreign curreny translation		40		· =	(70)		

Supplemental cash flow information (Note 14)

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

1. CORPORATE INFORMATION

CloudMD Software & Services Inc. ("CloudMD" or the "Company") is listed on the TSX Venture Exchange ("TSXV") under the trading symbol DOC, and is incorporated under the laws of British Columbia, Canada. The Company's corporate office is located at 810-789 West Pender Street, Vancouver, British Columbia, Canada, V6C 1H2.

CloudMD is an innovator in the delivery of healthcare services for individuals using a comprehensive personalized approach to support their mental, physical, and social issues. The Company's innovation comes from our ability to engage healthcare providers with productivity tools and personalized care plans that focus on health outcomes, supported through a connected care system that can engage and empower the individual in their care plan.

In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The ultimate duration of COVID-19, the magnitude of the impact on the economy, and the full extent to which COVID-19 may have direct and indirect impacts on CloudMD's business is not known at this time. This could include an impact on the Company's ability to obtain debt and equity financing, impairment in the value of long-lived assets, or potential future decrease in revenue or profitability of CloudMD's operations. The Company experienced an initial impact to its brick-and-mortar services, which the Company has been successful in mitigating with its telehealth services. Management has assessed that the Company's working capital is sufficient for it to continue as a going concern beyond one year.

2. SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of preparation

The condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard ("IAS") 34 Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB"). The Company has prepared the financial statements on the basis that it will continue to operate as a going concern. The Board of Directors considers that there are no material uncertainties that may cast significant doubt over this assumption. They have formed a judgment that there is a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future, and not less than 12 months from the end of the reporting period.

(b) Significant accounting policies

These condensed interim consolidated financial statements have been prepared in accordance with the accounting policies adopted in the Company's most recent annual financial statements for the year ended December 31, 2020, except for the following, which were adopted by the Company for the annual period beginning on January 1, 2021.

Investments in Associates and Joint Ventures

Investments in associates and joint ventures are accounted for using the equity method.

The carrying amount of the investment in associates and joint ventures is increased or decreased to recognize the Company's share of the profit or loss and other comprehensive income of the associate and joint venture, adjusted where necessary to ensure consistency with the accounting policies of the Company.

Unrealized gains and losses on transactions between the Company and its associates and joint ventures are eliminated to the extent of the Company's interest in those entities.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

Deferred Share Units ("DSUs")

DSUs are accounted for as cash-settled share-based payment transactions whereby the cost of the DSUs is measured initially at fair value based on the closing price of the Company's common shares preceding the day the DSUs are granted. The fair value of the DSUs is recognized as a liability in the statement of financial position and as a share-based compensation expense in the statement of net loss and comprehensive loss. The liability is remeasured to fair value based on the market price of the Company's common shares at each reporting date up to and including the settlement date, with changes in fair value recognized in share-based compensation expense in the statement of net loss and comprehensive loss.

(c) New standards, interpretations and amendments adopted by the Company

The Company has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. Several amendments to existing standards are effective from January 1, 2021, but they are not expected to have an impact on the condensed interim consolidated financial statements of the Company.

3. BUSINESS COMBINATIONS

(a) HumanaCare Organizational Resources Inc. ("HumanaCare")

On January 11, 2021, the Company completed the acquisition of HumanaCare by way of acquiring 100% of the issued and outstanding shares of First Health Care Services of Canada Inc. ("First Health"), which owned 100% of the issued and outstanding shares in the capital of HumanaCare. HumanaCare is an integrated Employee Assistance Program ("EAP") solution which provides compassionate, holistic, physical and mental health support for employees and their families. Pursuant to the share purchase agreement, the Company issued 2,369,791 common shares on January 11, 2021 and paid \$6,126 in cash to the former owners of First Health. The common shares will be subject to certain contractual restrictions on trading for a period of up to 25 months from the closing date.

Purchase consideration		
Fair value of common shares issued	\$	3,670
Cash consideration		6,126
Contingent shares issuable (1)		1,679
Total	\$	11,475
E-t		
Fair value of net assets acquired	Φ.	
Trade and other receivables	\$	673
Prepaid expenses, deposits and other		14
Property and equipment		320
Intangible assets		1
Accounts payable and accrued liabilities		(283)
Lease liabilities		(306)
Deferred revenue		(301)
Long-term debt		(262)
Total net assets acquired	\$	(144)
Goodwill	\$	11,619

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

(1) The contingent shares issuable represents two earn-out revenue milestone payments for the years ending December 31, 2021 and December 31, 2022. Preliminary valuation of the contingent shares issuable was calculated using the closing price of the Company's common shares on January 11, 2021 and the number of common shares issuable based on management's best estimate of future revenue results. The contingent shares issuable could be higher or lower depending on the related future revenue outcome.

The excess of the fair value of the purchase consideration over the fair values of the net assets acquired is considered as goodwill. Goodwill is attributable to the workforce, expected synergies and future profitability of the acquired business.

The above amounts included in the purchase price allocation are preliminary as management continues to gather relevant information that existed at the acquisition date to determine the fair value of the net identifiable assets acquired and liabilities assumed. The purchase price, including the fair value of common shares issued and contingent shares issuable, and the fair value of the net assets acquired and liabilities assumed are estimates, which were made by management at the time of the preparation of these condensed interim consolidated financial statements based on available information. Amendments may be made to these amounts, as well as the identification of intangible assets. Values based on estimates are subject to changes during the period ending 12 months after the acquisition date.

(b) Medical Confidence Inc. ("Medical Confidence")

On January 15, 2021, the Company completed the acquisition of 100% of the issued and outstanding shares of Medical Confidence. Medical Confidence offers a revolutionary healthcare navigation platform with proven results in wait time reduction and patient satisfaction. Pursuant to the share purchase agreement, as amended on April 30, 2021, the Company issued 857,143 common shares on January 15, 2021 and paid \$2,336 in cash to the former owners of Medical Confidence. The common shares will be subject to certain contractual restrictions on trading for a period of up to 20 months from the closing date.

Goodwill	\$	4,083
Total net assets acquired	\$	651
Long-term debt	ф.	(87)
Accounts payable and accrued liabilities		(284)
Intangible assets		520
Property and equipment		44
Trade and other receivables		297
Cash and cash equivalents	\$	161
Fair value of net assets acquired		
Total	Ψ	4,734
Contingent shares issuable (1) Total	<u> </u>	476 4,734
Contingent consideration (1)		533
Cash consideration		2,336
Fair value of common shares issued	\$	1,389
Purchase consideration		

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

The contingent consideration and contingent shares issuable represent two earn-out revenue milestone payments for the years ending December 31, 2021 and December 31, 2022. Preliminary valuation of the contingent consideration was calculated using the expected cash outflow based on management's best estimate of future revenue results. Preliminary valuation of the contingent shares issuable was calculated using the closing price of the Company's common shares on January 15, 2021 and the number of common shares issuable based on management's best estimate of future revenue results. The contingent consideration and contingent shares issuable could be higher or lower depending on the related future revenue outcome. The contingent consideration is reviewed and remeasured on a quarterly basis.

The excess of the fair value of the purchase consideration over the fair values of the net assets acquired is considered as goodwill. Goodwill is attributable to the workforce, expected synergies and future profitability of the acquired business.

The above amounts included in the purchase price allocation are preliminary as management continues to gather relevant information that existed at the acquisition date to determine the fair value of the net identifiable assets acquired and liabilities assumed. The purchase price, including the fair value of common shares issued, contingent consideration, contingent shares issuable, and the fair value of the net assets acquired and liabilities assumed are estimates, which were made by management at the time of the preparation of these condensed interim consolidated financial statements based on available information. Amendments may be made to these amounts, as well as the identification of intangible assets. Values based on estimates are subject to changes during the period ending 12 months after the acquisition date.

(c) Tetra Ventures LLC ("IDYA4")

On March 23, 2021, the Company completed the acquisition of 100% of the issued and outstanding membership interests of IDYA4. IDYA4 is a leading health technology company focused on data interoperability and cybersecurity based in the United States. Pursuant to the membership interest purchase agreement, the Company issued 3,889,169 common shares on March 23, 2021 and paid \$6,717 in cash to the former owners of IDYA4. The common shares will be subject to certain contractual restrictions on trading for a period of up to 30 months from the closing date.

Purchase consideration	
Fair value of common shares issued	\$ 4,897
Cash consideration	6,717
Contingent consideration (1)	199
Contingent shares issuable (1)	1,638
Total	\$ 13,451
Fair value of net assets acquired	
Cash and cash equivalents	\$ 1,772
Trade and other receivables	868
Intangible assets	440
Accounts payable and accrued liabilities	(1,010)
Total net assets acquired	\$ 2,070
Goodwill	\$ 11,381

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

The contingent consideration and contingent shares issuable represent two earn-out revenue milestone payments for the years ending December 31, 2021 and December 31, 2022. Preliminary valuation of the contingent consideration was calculated using the expected cash outflow based on management's best estimate of future revenue results. Preliminary valuation of the contingent shares issuable was calculated using the closing price of the Company's common shares on March 23, 2021 and the number of common shares issuable based on management's best estimate of future revenue results. The contingent consideration and contingent shares issuable could be higher or lower depending on the related future revenue outcome. The contingent consideration is reviewed and remeasured on a quarterly basis.

The excess of the fair value of the purchase consideration over the fair values of the net assets acquired is considered as goodwill. Goodwill is attributable to the workforce, expected synergies and future profitability of the acquired business.

The above amounts included in the purchase price allocation are preliminary as management continues to gather relevant information that existed at the acquisition date to determine the fair value of the net identifiable assets acquired and liabilities assumed. The purchase price, including the fair value of common shares issued, contingent consideration, contingent shares issuable, and the fair value of the net assets acquired and liabilities assumed are estimates, which were made by management at the time of the preparation of these condensed interim consolidated financial statements based on available information. Amendments may be made to these amounts, as well as the identification of intangible assets. Values based on estimates are subject to changes during the period ending 12 months after the acquisition date.

(d) Aspiria Corp ("Aspiria")

On April 1, 2021, the Company completed the acquisition of 100% of the issued and outstanding shares of Aspiria. Aspiria provides an Integrated Employee and Student Assistance Program ("SAP"), that focuses on a comprehensive suite of mental health and wellness solutions for all employer and educational sectors. Pursuant to the share purchase agreement, the Company issued 460,526 common shares on April 1, 2021 and paid \$889 in cash to the former owners of Aspiria. The common shares will be subject to certain contractual restrictions on trading for a period of up to 30 months from the closing date.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

Purchase consideration	
Fair value of common shares issued	\$ 587
Cash consideration	889
Contingent shares issuable ⁽¹⁾	617
Total	\$ 2,093
Fair value of net assets acquired	
Cash and cash equivalents	\$ 85
Trade and other receivables	96
Prepaid expenses, deposits and other	13
Property and equipment	159
Intangible assets	1
Goodwill	481
Accounts payable and accrued liabilities	(565)
Deferred revenue	(27)
Lease liabilities	(147)
Total net assets acquired	\$ 96
Goodwill	\$ 1,997

⁽¹⁾ The contingent shares issuable represents an earn-out revenue milestone payment for the year ending December 31, 2021. Preliminary valuation of the contingent shares issuable was calculated using the closing price of the Company's common shares on April 1, 2021 and the number of common shares issuable based on management's best estimate of future revenue results. The contingent shares issuable could be higher or lower depending on the related future revenue outcome.

The excess of the fair value of the purchase consideration over the fair values of the net assets acquired is considered as goodwill. Goodwill is attributable to the workforce, expected synergies and future profitability of the acquired business.

The above amounts included in the purchase price allocation are preliminary as management continues to gather relevant information that existed at the acquisition date to determine the fair value of the net identifiable assets acquired and liabilities assumed. The purchase price, including the fair value of common shares issued and contingent shares issuable, and the fair value of the net assets acquired and liabilities assumed are estimates, which were made by management at the time of the preparation of these condensed interim consolidated financial statements based on available information. Amendments may be made to these amounts, as well as the identification of intangible assets. Values based on estimates are subject to changes during the period ending 12 months after the acquisition date.

(e) Rx Infinity Inc., Rxi Pharmacy Inc. and Rxi Health Solutions Inc. (collectively "Rxi")

On May 11, 2021, the Company completed the acquisition of 100% of the issued and outstanding shares of Rxi. Rxi provides pharmaceutical logistic services including drug distribution, patient navigation assistances, a preferred pharmacy network of over 500 pharmacies and real time universal disease management software. Pursuant to the share purchase agreement, the Company issued 1,673,640 common shares on May 11, 2021 and paid \$2,750 in cash to the former owners of Rxi, of which \$346 is receivable from the former owners of Rxi due to an estimated net working capital adjustment as at September 30, 2021. The common shares will be subject to certain contractual restrictions on trading for a period of up to 20 months from the closing date.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

Purchase consideration	
Fair value of common shares issued	\$ 2,595
Cash consideration	2,404
Contingent consideration (1)	637
Total	\$ 5,636
Fair value of net assets acquired	
Cash and cash equivalents	\$ 631
Trade and other receivables	2,366
Prepaid expenses, deposits and other	6
Inventory	43
Property and equipment	693
Intangible assets	1
Accounts payable and accrued liabilities	(2,930)
Lease liabilities	(115)
Total net assets acquired	\$ 695
Goodwill	\$ 4,941

⁽¹⁾ The contingent consideration represents two earn-out profitability milestone payments for the years ending December 31, 2021 and December 31, 2022. Preliminary valuation of the contingent consideration was calculated using the closing price of the Company's common shares on May 11, 2021 and the number of common shares issuable based on management's best estimate of future profitability results. The contingent consideration could be higher or lower depending on the related future profitability outcome. The contingent consideration is reviewed and remeasured on a quarterly basis.

The excess of the fair value of the purchase consideration over the fair values of the net assets acquired is considered as goodwill. Goodwill is attributable to the workforce, expected synergies and future profitability of the acquired business.

The above amounts included in the purchase price allocation are preliminary as management continues to gather relevant information that existed at the acquisition date to determine the fair value of the net identifiable assets acquired and liabilities assumed. The purchase price, including the fair value of common shares issued, contingent consideration, and the fair value of the net assets acquired and liabilities assumed are estimates, which were made by management at the time of the preparation of these condensed interim consolidated financial statements based on available information. Amendments may be made to these amounts, as well as the identification of intangible assets. Values based on estimates are subject to changes during the period ending 12 months after the acquisition date.

(f) 0869316 BC Ltd., 1143556 BC Ltd. and 1153046 BC Ltd. (collectively "VisionPros")

On June 23, 2021, the Company completed the acquisition of 100% of the issued and outstanding shares of VisionPros. VisionPros is a vertically integrated digital eyewear platform servicing customers across North America. Pursuant to the share purchase agreement, the Company agreed to issue 9,818,181 common shares of the Company and pay \$26,005 in cash to the former owners of VisionPros, of which \$2,226 is receivable from the former owners of VisionPros due to an estimated net working capital adjustment as at September 30, 2021. There is an indemnification holdback of a further 1,090,909 shares and \$3,000 of cash payable to the former owners of VisionPros for a period of up to two years following the closing date. The common shares will be subject to certain contractual restrictions on trading for a period of up to 24 months from the closing date.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

The purchase price, determined by the fair value of the consideration given at the date of the acquisition and the fair value of the net assets acquired on the date of the acquisition, was as follows:

Purchase consideration		
Fair value of common shares issued	\$	13,511
Cash consideration		23,779
Shares under escrow		1,501
Indemnification holdback		3,000
Contingent consideration ⁽¹⁾		4,786
Total	\$	46,577
Fair value of net assets acquired		
Cash and cash equivalents	\$	161
Trade and other receivables		1,602
Prepaid expenses, deposits and other		35
Inventory		2,622
Property and equipment		770
Intangible assets		1
Accounts payable and accrued liabilities		(6,657)
Lease liabilities		(43)
Long-term debt		(60)
Total net assets acquired	\$	(1,568)
Goodwill	<u> </u>	48,145

⁽¹⁾ The contingent consideration represents two earn-out revenue-based milestone payments for the years ending December 31, 2021 and December 31, 2022. The contingent consideration can be settled using cash or common shares at the Company's discretion. Preliminary valuation of the contingent consideration was calculated using the expected cash outflow based on management's best estimate of future revenue-based results. The contingent consideration could be higher or lower depending on the related future revenue-based outcome. The contingent consideration is reviewed and remeasured on a quarterly basis.

The excess of the fair value of the purchase consideration over the fair values of the net assets acquired is considered as goodwill. Goodwill is attributable to the workforce, expected synergies and future profitability of the acquired business.

The above amounts included in the purchase price allocation are preliminary as management continues to gather relevant information that existed at the acquisition date to determine the fair value of the net identifiable assets acquired and liabilities assumed. The purchase price, including the fair value of common shares issued, contingent consideration, and the fair value of the net assets acquired and liabilities assumed are estimates, which were made by management at the time of the preparation of these condensed interim consolidated financial statements based on available information. Amendments may be made to these amounts, as well as the identification of intangible assets. Values based on estimates are subject to changes during the period ending 12 months after the acquisition date.

(g) Oncidium Inc. ("Oncidium")

On June 25, 2021, the Company completed the acquisition of 100% of issued and outstanding share of Oncidium. Inc. Oncidium is a Canadian healthcare provider to employers. Pursuant to the share purchase agreement, the Company issued 16,521,739 common shares on June 25, 2021 and paid \$28,976 in cash to the former owners of Oncidium. There is a working capital holdback of \$500 of cash payable to the former owners. The common shares will be subject to certain contractual restrictions on trading for a period of up to 30 months from the closing date.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

The purchase price, determined by the fair value of the consideration given at the date of the acquisition and the fair value of the net assets acquired on the date of the acquisition, was as follows:

Purchase consideration	
Fair value of common shares issued	\$ 25,157
Cash consideration	28,976
Working capital holdback	500
Contingent consideration ⁽¹⁾	26,702
Total	\$ 81,335
Fair value of net assets acquired	
Cash and cash equivalents	\$ 1,560
Trade and other receivables	8,033
Prepaid expenses, deposits and other	1,506
Property and equipment	4,061
Intangible assets	1,384
Deferred tax assets	2,500
Goodwill	23,430
Accounts payable and accrued liabilities	(12,306)
Lease liabilities	(3,680)
Total net assets acquired	\$ 26,488
Goodwill	\$ 54.847

⁽¹⁾ The contingent consideration represents three revenue and three profitability earn-out milestone payments for the years ending December 31, 2021, December 31, 2022 and December 31, 2023. The contingent consideration can be settled using cash or common shares at the Company's discretion. Preliminary valuation of the contingent consideration was calculated using the expected cash outflow based on management's best estimate of future revenue and profitability results. The contingent consideration could be higher or lower depending on the related future revenue and profitability outcome. The contingent consideration is reviewed and remeasured on a quarterly basis.

The excess of the fair value of the purchase consideration over the fair values of the net assets acquired is considered as goodwill. Goodwill is attributable to the workforce, expected synergies and future profitability of the acquired business.

The above amounts included in the purchase price allocation are preliminary as management continues to gather relevant information that existed at the acquisition date to determine the fair value of the net identifiable assets acquired and liabilities assumed. The purchase price, including the fair value of common shares issued, contingent consideration, and the fair value of the assets acquired and liabilities assumed are estimates, which were made by management at the time of the preparation of these condensed interim consolidated financial statements based on available information. Amendments may be made to these amounts, as well as the identification of intangible assets. Values based on estimates are subject to changes during the period ending 12 months after the acquisition date

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

4. INVESTMENT IN JOINT VENTURE

On February 8, 2021, the Company acquired 51% of the issued and outstanding shares in West Mississauga Medical Ltd. ("West Mississauga"), a joint venture providing comprehensive family medicine and a specialist medical clinic with 8 family doctors and 4 specialists serving over 100,000 patients. Ownership was acquired in exchange for the issuance of 74,074 common shares on February 8, 2021 and the payment of \$181 in cash. Under the terms of the shareholder agreement, CloudMD is able to appoint one of two directors of West Mississauga and all critical decisions require unanimous consent of the shareholders of West Mississauga. West Mississauga is structured as a separate vehicle and the Company has a residual interest in the net assets of West Mississauga. As a result, the Company treated its investment of West Mississauga as a joint venture and is accounted for using the equity method.

The activities of the Company's investment in West Mississauga Medical Ltd. during the period were as follows:

Balance, January 1, 2021	\$ -
Investment in joint venture	310
Share in profits for the period	9
Balance, September 30, 2021	\$ 319

5. REVENUE

	Three me	on	ths ended		Nine months ended						
	September 30,		eptember 30, September 30,				September 30,				
	2021		2020		2021		2020				
Clinics & pharmacies	\$ 9,553	\$	2,900	\$	19,928	\$	7,860				
Digital health solutions	10,039		459		16,471		1,345				
Enterprise health solutions	19,570		-		27,197		-				
Total revenues	\$ 39,162	\$	3,359	\$	63,596	\$	9,205				

6. EXPENSES BY NATURE

	Three mo	nths ended	Nine mor	ths ended	
	September 30, 2021	September 3	30,	September 30, 2021	September 30, 2020
Cost of sales and other	\$ 31,767	\$ 3,	770 \$	\$ 54,908	\$ 9,770
Wages and employee benefits	8,611	1,	148	16,870	3,976
Share-based compensation	1,543	:	559	4,576	1,508
Amortization of intangible assets	307		63	758	186
Depreciation of property and equipment	776		199	1,843	487
Total	\$ 43,004	\$ 6,	039 \$	\$ 78,955	\$ 15,927

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

7. PROPERTY AND EQUIPMENT

	Equipment and				Leasehold			Right-of-use	
		other		Computers		improvements		assets	Total
Cost									
Balance, January 1, 2020	\$	167	\$	31	\$	81	\$	2,725	\$ 3,004
Business combinations		370		37		892		1,570	2,869
Additions		59		28		63		1,034	1,184
Disposals		(2)		(1)		(6)		-	(9)
Foreign exchange differences		(2)		-		(6)		-	(8)
Balance, December 31, 2020		592		95		1,024		5,329	7,040
Business combinations		1,279		193		243		4,326	6,041
Additions		204		265		54		1,736	2,259
Disposals		-		-		-		(34)	(34)
Foreign exchange differences		(3)		-		-		-	(3)
Balance, September 30, 2021	\$	2,072	\$	553	\$	1,321	\$	11,357	\$ 15,303
Accumulated Depreciation									
Balance, January 1, 2020	\$	22	\$	12	\$	17	\$	345	\$ 396
Depreciation		72		28		111		648	859
Disposals		(2)		(1)		(4)		-	(7)
Balance, December 31, 2020		92		39		124		993	1,248
Depreciation		268		69		164		1,342	1,843
Disposals		-		-		-		(23)	(23)
Balance, September 30, 2021	\$	360	\$	108	\$	288	\$	2,312	\$ 3,068
Net Book Value									
At December 31, 2020	\$	500	\$	56	\$	900	\$	4,336	\$ 5,792
At September 30, 2021	\$	1,712		445	- 1	1,033	- :	9,045	12,235

For the three and nine months ended September 30, 2021, the Company recorded depreciation expense of \$776 and 1.843 (2020 – \$199 and \$487) within expenses.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

8. GOODWILL AND INTANGIBLE ASSETS

	Customer relationships	Content Licenses	Brands	Technology platforms	Assets under development	Total intangible assets	Goodwill
Cost							
Balance, January 1, 2020	\$ 1,368	\$ -	\$ -	\$ 885	\$ -	\$ 2,253	\$ 9,498
Business combinations	209	90	737	5,557	-	6,593	34,761
Additions	5	_	_	5	-	10	-
Balance, December 31, 2020	1,582	90	737	6,447	-	8,856	44,259
Business combinations	1,496	-	_	525	327	2,348	160,924
Additions	387	-	-	1,254	399	2,040	-
Balance, September 30, 2021	\$ 3,465	\$ 90	\$ 737	\$ 8,226	\$ 726	\$ 13,244	\$ 205,183
Accumulated Amortization Balance, January 1, 2020 Amortization	\$ 75 148	\$ - -	\$ - -	\$ 82 367	\$ - -	\$ 157 515	\$ - -
Balance, December 31, 2020	223	-	-	449	-	672	-
Amortization	213	-	_	545	-	758	-
Balance, September 30, 2021	\$ 436	\$ -	\$	\$ 994	\$ -	\$ 1,430	\$
Net Book Value							
At December 31, 2020	\$ 1,359	\$ 90	\$ 737	\$ 5,998	\$ -	\$ 8,184	\$ 44,259
At September 30, 2021	\$ 3,029	\$ 90	\$ 737	\$ 7,232	\$ 726	\$ 11,814	\$ 205,183

For the three and nine months ended September 30, 2021, the Company recorded amortization expense of \$307 and \$758 (2020 - \$63 and \$186) within expenses.

The Company did not identify any indicators of impairment for the three and nine months ended September 30, 2021.

9. LONG-TERM DEBT

			Se	ptember 30,	Dece	ember 31,
	Interest rate	Maturity		2021		2020
	3.20%	October 31, 2026	\$	164	\$	186
Fixed interest rate bank loans (1)	3.35%	December 31, 2022		1,375		1,559
	3.97%	October 31, 2026		165		187
	CDOR +3.50% (2)	June 30, 2024		23,107		338
Variable interest rate bank loans	Prime +1.00% (3)	April 30, 2023		119		175
	Prime + 0.50%			-		95
Interest free loans						
RRRF Loan				-		38
CEBA Loan				60		68
Balance				24,990		2,646
Current portion				2,408		619
Long-term portion			\$	22,582	\$	2,027

⁽¹⁾ The fixed interest rate bank loans are secured by first ranking security interest over all property of CloudMD and certain subsidiaries for a maximum guarantee amount of \$3,414.

Effective June 25, 2021, the Company, through its subsidiary Oncidium, established credit facilities of up to

⁽²⁾ As at September 30, 2021, the interest rate for the variable interest rate bank loan was 4.19%.

⁽³⁾ As at September 30, 2021, the interest rate for the variable interest rate bank loan was 3.45%.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

\$62,000 (the "Facilities") comprised of the following:

- (1) Revolver Facility of \$3,000; and,
- (2) Term Facility of \$59,000.

The Facilities mature three years from the date the funds are drawn. Interest accrues daily on advances at the applicable Canadian Dealer Offered Rate ("CDOR") plus a margin of between 2.0% and 3.5% dependent upon certain financial ratios. The fair value of the long-term debt approximates its carrying value.

As at September 30, 2021, the Company was in compliant with all financial covenants.

The debt is secured by a first-ranking security interest on all of Oncidium's present and after-acquired assets.

10. CONTINGENT CONSIDERATION

The following table shows a reconciliation of the contingent consideration liability:

Contingent consideration, December 31, 2019	\$ -
Contingent consideration for business combinations	1,470
Change in fair value	(140)
Contingent consideration, December 31, 2020	1,330
Contingent consideration for business combinations	32,857
Payment of contingent consideration	(135)
Accretion expense	307
Change in fair value	(966)
Contingent consideration, September 30, 2021	33,393
Current portion	14,919
Long-term portion	\$ 18,474

The estimated amounts payable related to the contingent consideration is measured at fair value based on unobservable inputs and is considered a Level 3 financial instrument. The determination of the fair value of contingent consideration is primarily driven by the Company's estimates of the respective acquired entities in achieving milestones based on financial targets and could be higher or lower depending on the related future performance outcome. Significant increases or decreases in related financial measures would result in a higher or lower fair value of the contingent consideration liability, while significant increases or decreases in the discount rate and performance risk would result in a lower or higher fair value of the liability.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

11. LEASES

The Company leases various office, clinic, and pharmacy spaces for its operations. The Company also subleases certain excess space to a third party.

(a) As a lessee

The following is a continuity schedule of the Company's lease liabilities:

Balance, December 31, 2019	\$ 2,438
Lease renewal	1,034
Additions from business combinations	1,806
Interest expense on lease liabilities	140
Lease payments	(754)
Balance, December 31, 2020	4,664
Additions	1,708
Additions from business combinations	4,283
Interest expense on lease liabilities	211
Lease payments	(1,527)
Lease terminations	(11)
Balance, September 30, 2021	9,328
Current portion	2,139
Long-term portion	\$ 7,189

The following is a breakdown of contractual undiscounted cash flows for lease liabilities by maturities as at September 30, 2021:

	September 30,
	2021
Less than one year	\$ 2,452
One to five years	6,766
More than five years	1,054
Total	\$ 10,272

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

12. RELATED PARTY TRANSACTIONS

Related parties include key management, the Board of Directors, close family members and enterprises which are controlled by these individuals. The below transactions are in the normal course of business and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

Remuneration of key management and Board of Directors:

		Three mo	nths e		ended			
	Se	September 30, S			Sep	tember 30,	Sep	ptember 30,
		2021		2020		2021	2020	
Cash-based compensation	\$	333	\$	204	\$	1,176	\$	521
Share-based compensation		1,311		231		2,559		644
Total	\$	1,644	\$	435	\$	3,735	\$	1,165

13. SHARE CAPITAL

(a) Authorized: unlimited common shares without par value

(b) Issued and outstanding

The following is a summary of share capital activities:

	Number of	Share
	common shares	capital
Balance, December 31, 2019	81,213,470 \$	16,792
Shares issued for business combinations	11,640,219	16,994
Shares issued for settlement of Livecare debt	1,500,000	578
Private placements	6,298,615	3,023
Bought deal financing	51,947,800	73,000
Share issuance costs	294,035	(9,681)
Exercise of stock options	1,928,250	2,066
Exercise of warrants	9,183,070	9,170
Shares issued for services	900,000	409
Balance, December 31, 2020	164,905,459	112,351
Shares issued for business combinations	35,809,217	51,916
Shares issued for investment in joint venture	74,074	129
Shares issued for asset purchase	574,468	1,108
Bought deal financing	21,560,000	58,212
Contingent shares issued	568,182	1,461
Share issuance costs	-	(5,749)
Exercise of stock options	2,161,500	2,040
Exercise of restricted share units	256,000	470
Exercise of warrants	3,819,837	3,167
Shares issued for services	1,741,392	2,455
Balance, September 30, 2021	231,470,129 \$	227,560

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

(c) Bought deal financing

	Type	Shares issued	ercise rice	Gross roceeds	is	Share suance costs	Agent warrants issued ⁽¹⁾	xercise orice
March 2021	Bought deal	21,560,000	\$ 2.70	\$ 58,212	\$	5,749	1,509,200	\$ 2.70

⁽¹⁾ Each warrant is exercisable to acquire one common share of the Company for a period of 2 years from the closing date of the offering.

(d) Agents' warrants

The following is a summary of agents' warrants activities during the nine months ended September 30, 2021:

	Number of Agents'	Weighted Average Exercise
	Warrants	Price
Balance outstanding, December 31, 2019	501,520	0.76
Issued	4,473,447	1.35
Exercised	(3,131,096)	(0.91)
Balance outstanding, December 31, 2020	1,843,871	1.94
Issued	1,509,200	2.70
Exercised	(3,437)	(0.48)
Balance outstanding, September 30, 2021	3,349,634	2.28

As at September 30, 2021, the Company had the following agents' warrants outstanding, all of which were exercisable:

	Age	nts' warrants outstandir	ıg			
	Number of	Weighted average	Weighted			
Range of exercise prices	agents' warrants	remaining contractual	average			
	outstanding	life (years)	exercise price			
\$0.00 to \$0.50	22,676	0.47	\$ 0.48			
\$0.51 to \$1.00	149,504	0.67	1.00			
\$1.01 to \$1.50	581,504	0.98	1.38			
\$2.01 to \$2.50	1,086,750	1.11	2.40			
\$2.51 to \$3.00	1,509,200	1.44	2.70			
	3,349,634	_				

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2021 and 2020

(Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

(e) Shareholders' warrants

The following is a summary of shareholders' warrants activities during the nine months ended September 30, 2021:

	Number of Shareholders'	Weighted Average
	Warrants	Exercise Price
Balance outstanding, December 31, 2019	4,492,344	\$ 0.80
Issued	13,828,206	-
Exercised	(6,051,974)	(0.83)
Balance outstanding, December 31, 2020	12,268,576	0.93
Issued	-	-
Exercised	(3,816,400)	(0.83)
Expired	(230,769)	(1.00)
Balance outstanding, September 30, 2021	8,221,407	\$ 0.98

As at September 30, 2021, the Company has 8,221,407 shareholders' warrants outstanding with the exercise price ranging from \$0.51 to \$1.00, the weighted average exercise price and remaining contractual life is \$0.98 and 0.66 years, respectively. The shareholders' warrants have a fair value of \$nil, valued using the residual value method.

(f) Shares under trading restrictions

As at September 30, 2021, the Company has issued 42,163,824 common shares that were subject to trading restrictions (December 31, 2020 - 18,263,173).

(g) Stock options

The following is a summary of activity in the Company's incentive stock option plan:

	Number of Stock Options	Weighted Average Exercise Price			
Balance outstanding, December 31, 2019	5,250,000	\$ 0.60			
Granted	7,449,000	1.30			
Exercised	(1,928,250)	0.53			
Forfeited	(118,750)	0.44			
Balance outstanding, December 31, 2020	10,652,000	1.08			
Granted	1,985,000	2.00			
Exercised	(2,161,500)	0.59			
Forfeited	(150,000)	1.91			
Balance outstanding, September 30, 2021	10,325,500	\$ 1.34			

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

As at September 30, 2021, the Company had the following stock options outstanding and exercisable:

Options outstanding Options exe							
Range of exercise prices Number of options outstanding			Weighted average remaining contractual life (years)	Weighted average exercise price	Number of options exercisable	Weighted average exercise price	
\$0.00 to	\$0.50	3,017,500	3.13	\$ 0.49	2,857,750	\$ 0.49	
\$0.51 to	\$1.00	2,235,000	3.04	0.73	2,072,500	0.73	
\$1.01 to	\$1.50	400,000	3.91	1.38	200,000	1.38	
\$1.51 to	\$2.00	1,460,000	4.32	1.78	230,000	2.00	
\$2.01 to	\$2.50	3,100,000	4.19	2.36	1,177,500	2.29	
\$2.51 to	\$3.00	113,000	4.04	2.56	56,500	2.56	
		10,325,500			6,594,250		

The following weighted average assumptions were used in calculating the fair value of stock options granted during the period using the Black-Scholes model:

	Three months ended							
	September 30, 2021	September 30, 2020						
Expected option life	5 years	5 years						
Risk-free interest rate	1.11%	0.35%						
Dividend yield	0%	0%						
Volatility rate	60%	100%						
Forfeiture rate	0%	0%						

(h) Restricted Share Units ("RSU")

The following is a summary of activity in the Company's RSU plan:

	Number of Restricted Share Units
Balance outstanding, December 31, 2020	-
Granted	936,000
Exercised	(256,000)
Balance outstanding, September 30, 2021	680,000

(i) Deferred Share Units ("DSU")

Effective May 1, 2021, the Company adopted a cash-settled DSU plan for its independent directors (the "DSU Plan"), which provides that the Board of Directors may, from time to time, award DSUs in its discretion to the independent directors. All DSUs granted vest immediately and are credited to each independent directors' account.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

The following is a summary of activity in the Company's DSU plan:

	Number of
	Deferred
	Share Units
Balance outstanding, December 31, 2020	-
Issued	140,000
Balance outstanding, September 30, 2021	140,000

(j) Share-based compensation

		Three mor	nths	ended	Nine months ended				
	September 30, 2021		September 30, 2020		Sep	otember 30, 2021	September 30, 2020		
Stock options	\$	1,077	\$	559	\$	3,650	\$	1,508	
RSUs		364		-		712		-	
DSUs		102		-		214		_	
Total share-based compensation expense	\$	1,543	\$	559	\$	4,576	\$	1,508	

14. SUPPLEMENTAL CASH FLOW INFORMATION

(a) Cash and cash equivalents

	Sep	tember 30, 2021	December 31, 2020			
Cash	\$	20,523	\$ 41,658			
Cash equivalents		33,162	18,056			
Total	\$	53,685	\$ 59,714			

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

(b) Other cash flow information

	Three months ended					Nine months ended				
	Se	ptember 30, 2021	September 30, 2020			September 30, 2021	September 30, 2020			
Change in non-cash working capital										
Trade and other receivables	\$	(2,375)	\$	(6)	\$	(3,828)	\$	(75)		
Inventory		(179)		(42)		(12)		5		
Prepaid expenses, deposits and other		(736)		310		(869)		113		
Accounts payable, accrued liabilities and other		(709)		(110)		(685)		21		
Deferred revenue		(218)		(6)		373		-		
	\$	(4,217)	\$	146	\$	(5,021)	\$	64		
Non-cash investing and financing activities										
Shares issued for acquisition of Livecare	\$	_	\$	_	\$	_	\$	663		
Shares issued for acquisition of Livecare debt	·	_	·	_	·	_		600		
Shares issued for acquisition of South Surrey		110		_		110		380		
Shares issued for acquisition of HumanaCare		-		_		3,670		-		
Shares issued for acquisition of Medical						-,				
Confidence		_		_		1,389		_		
Shares issued for acquisition of IDYA4		_		_		4,897		_		
Shares issued for acquisition of Aspiria		_		_		587		_		
Shares issued for acquisition of Rxi		_		_		2,595		_		
Shares issued for acquisition of VisionPros		_		_		13,511		_		
Shares issued for acquisition of Oncidium		_		_		25,157		_		
Shares issued for investment in joint venture		_		_		129		_		
Shares issued for asset purchase		-		-		1,108		-		
Shares issued for services		_		_		2,455		409		
Issuance of agent warrants as share issuance						,				
costs		-		497		1,528		685		
Other cash flow information										
Cash received for interest	\$	37	\$	_	\$	166	\$	_		
Cash paid for interest	т	(251)	-	(30)	7	(315)	-	(66)		
Cash paid for income taxes		(102)		-		(257)		-		

15. CAPITAL MANAGEMENT

The Company's objectives when managing capital are to safeguard its ability to continue as a going concern and to maximize shareholder value. The Company's capital is comprised of equity and long-term debt, net of cash and cash equivalents. The Company manages the capital structure and adjusts in response to changes in economic conditions and the risk characteristics of the underlying assets. To secure the additional capital necessary to pursue these plans, the Company intends to raise additional funds through equity or debt financing.

There were no changes to the Company's approach in its management of capital during the period.

The Company is subject to certain financial covenants in its debt obligations. The Company's strategy is to ensure it remains in compliance with all of its existing covenants so as to ensure continuous access to required debt to fund growth. Management reviews results and forecasts to monitor the Company's compliance.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

16. FINANCIAL INSTRUMENTS

The Company's principal financial assets include cash and cash equivalents, and trade and other receivables. The Company's principal financial liabilities comprise of accounts payable and accrued liabilities, contingent consideration, contingent liability and long-term debt. The main purpose of these financial liabilities is to finance the Company's operations.

The carrying values of cash and cash equivalents, trade and other receivables, and accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term nature of these instruments. The carrying value of long-term debt is initially recognized at fair value and subsequently measured at amortized cost using the effective interest method. There were no transfers between levels of the fair value hierarchy.

The Company is exposed to credit risk, liquidity risk and market risk. The Company's senior management oversees the management of these risks.

Credit risk

Credit risk is the risk of loss associated with a counterparty's inability to fulfill its payment obligations. Credit risk arises from cash and cash equivalents, and trade and other receivables. To manage credit risk, cash and cash equivalents are held only with reputable and regulated financial institutions.

The Company provides credit to its customers in the normal course of operations. The Company minimizes its credit risk associated with its trade and other receivables by performing credit evaluations on customers, maintaining regular and ongoing contact with customers, routinely reviewing the status of individual trade and other receivables balances and following up on overdue amounts. Further, trade receivables are monitored on a periodic basis for assessing any significant risk of non-recoverability of dues and provision is created accordingly.

The Company's exposure to credit risk is considered to be low, given the size and nature of the various counterparties involved and their history of collections.

As at September 30, 2021, the Company had \$22,261 (December 31, 2020 – \$2,012) of trade and other receivables, net of an allowance for doubtful accounts of \$283 (December 31, 2020 - \$157).

Liquidity risk

Liquidity risk is the risk that the Company cannot meet a demand for cash or fund its obligations as they become due. The Company's management is responsible for reviewing liquidity resources to ensure funds are readily available to meet its financial obligations as they become due, as well as ensuring adequate funds exist to support business strategies and operational growth. The current assets reflected on the statement of financial position are highly liquid.

Notes to the Condensed Interim Consolidated Financial Statements

For the three and nine months ended September 30, 2021 and 2020

(Expressed in thousands of Canadian Dollars, except number of shares and per share amounts)

(Unaudited)

The maturity profile of the Company's financial liabilities, based on contractual undiscounted payment at each reporting date is:

As at September 30, 2021

	Less than one			One to five	Mo	ore than five	
		year		years		years	Total
Accounts payable, accrued liabilities and other	\$	27,535	\$	-	\$	-	\$ 27,535
Contingent consideration		15,045		18,725		-	33,770
Long-term debt		2,940		23,393		6	26,339
	\$	45,520	\$	42,118	\$	6	\$ 87,644

As at December 31, 2020

	Less than one		(One to five	More than five			
		year		years		years		Total
Accounts payable, accrued liabilities and other	\$	3,453	\$	-	\$	-	\$	3,453
Contingent consideration		145		-		-		145
Long-term debt		619		1,969		58		2,646
	\$	4,217	\$	1,969	\$	58	\$	6,244

Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Company is exposed to interest rate risk and foreign currency risk.

(a) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's long-term debt obligations with floating interest rates.

At September 30, 2021, the Company had variable rate borrowing rate loans amounting to \$23,253 (December 31, 2020 - \$608). With all other variables held constant, a 1% increase in the interest rate would have increased net loss by approximately \$116 (2020 - \$3) for the nine months ended September 30, 2021. There would be an equal and opposite impact on net loss with a 1% decrease in the interest rate.

(b) Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Company's exposure to the risk of changes in foreign exchange rates relates primarily to the Company's operating activities (when revenue or expense is denominated in a foreign currency) and the Company's net investments in foreign subsidiaries.

At September 30, 2021, the Company held net monetary assets in United States dollar ("USD") equal to \$3,896 (December 31, 2020 – \$545). The Company estimates the impact of a 5% change in the Canadian dollar exchange rate on its net monetary assets to be \$195 (December 31, 2020 – \$35).

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

17. SEGMENTED INFORMATION

The Company has three operating segments and the Company's chief operating decision-maker is the Chief Executive Officer.

Clinics & Pharmacies

Clinics & Pharmacies operates a series of hybrid medical clinics located in British Columbia and Ontario, including telemedicine services. This division is focused on providing healthcare services, with the support of doctors, within the context of publicly accessible healthcare services that are reimbursed by the applicable health authorities. To the extent there are services rendered by the Company that are not eligible for reimbursement, such services are charged directly to patients and/or third parties.

Digital Health Solutions

Digital Health Solutions are offered on a subscription or license to use basis. The solutions are sold to companies, insurers, clinics and pharmacies (including those owned by the Company) who use our technology to create connectivity, and improve the healthcare practitioner, client and user experience while creating efficiencies in administration.

Enterprise Health Solutions

Enterprise Health Solutions provides organizations with physical and mental health navigation and treatment through employee support services. Revenues within this division is earned through two pricing models:

- Subscription-based pricing model using a price per member per month with an average contractual term of 3 years; and,
- Per-case billing model at an agreed upon rate for services that are used in disability management, occupational health, and other employer services.

A breakdown of revenue and cost of sales for each operating segment for the three and nine months ended September 30, 2021 and 2020 is as follows:

Three months ended September 30, 2021	Clinics & Pharmacies	Digital Health Solutions	Enterprise Health Solutions	Total
Revenue	\$ 9,553	\$ 10,039	\$ 19,570	\$ 39,162
Cost of sales	8,232	6,459	11,175	25,866
Gross profit	\$ 1,321 \$	\$ 3,580	\$ 8,395	\$ 13,296

Three months ended September 30, 2020	Clinics & Pharmacies	Digital Health Solutions	Enterprise Health Solutions	Total
Revenue	\$ 2,900	\$ 459	\$ -	\$ 3,359
Cost of sales	1,970	130	-	2,100
Gross profit	\$ 930	\$ 329	\$ -	\$ 1,259

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

Nine months ended September 30, 2021	Clinics & Pharmacies	Digital Health Solutions	Enterprise Health Solutions		Total
Revenue	\$ 19,928	\$ 16,471	\$ 27,197 \$	6	63,596
Cost of sales	16,020	9,789	15,343		41,152
Gross profit	\$ 3,908	\$ 6,682	\$ 11,854 \$	}	22,444

Nine months ended September 30, 2020	Clinics & Pharmacies	Digital Health Solutions	Enterprise Health Solutions	Total
Revenue	\$ 7,860	\$ 1,345	\$ -	\$ 9,205
Cost of sales	5,412	380		5,792
Gross profit	\$ 2,448 \$	\$ 965	\$ -	\$ 3,413

See below segmented geographical information as follows:

	S	eptember 30,	December 31,
Non-Current Assets		2021	2020
Canada	\$	213,279	\$ 51,766
United States		18,704	6,727
Total	\$	231,983	\$ 58,493

		Three mo	nths ended	Nine mon	ths ended
	Se	ptember 30,	September 30,	September 30,	September 30,
Revenue		2021	2020	2021	2020
Canada	\$	31,737	\$ 3,359	\$ 51,513	\$ 9,205
United States		7,425	-	12,083	-
Total	\$	39,162	\$ 3,359	\$ 63,596	\$ 9,205

18. LITIGATION AND OTHER CONTINGENCIES

(a) During the three months ended June 30, 2020, Gravitas Securities Inc. ("Gravitas") commenced an arbitration alleging breach of the terms of a right of first refusal in connection with an offering which was in the form of a bought deal equity financing underwritten by a syndicate of other investment banks in May 2020, and was completed on June 2, 2020 (the "June 2020 Financing"). During the three months ended September 30, 2020, Gravitas amended its claims for damages to include commissions and damages arising from an additional bought deal equity financing which was completed on September 22, 2020 (the "September 2020 Financing"). During the three months ended June 30, 2021, Gravitas amended its claim for damages to include commissions and damages arising from an additional bought deal equity financing which was completed on March 12, 2021 (the "March 2021 Financing"). The total claims are in excess of \$6,850 plus unspecified damages associated with the value of share purchase warrants that were issued in connection with the June 2020 Financing, the September 2020 Financing, and the March 2021 Financing, plus interest and cost. The Company disputes the claims with respect to each of the June 2020 Financing, the September 2020 Financing, and the March 2021 Financing entirely. The claims are currently subject to arbitration proceedings which the Company is defending, and the arbitration is scheduled to proceed to a final hearing in April 2022. The Company is of the view that its defense to the claims will prevail without liability to the Company; however, an estimate of the liability to the Company should the Gravitas claims succeed is \$1,200 and therefore an accrual for that amount as a contingent liability has been recorded.

Notes to the Condensed Interim Consolidated Financial Statements For the three and nine months ended September 30, 2021 and 2020 (Expressed in thousands of Canadian Dollars, except number of shares and per share amounts) (Unaudited)

(b) On September 29, 2020, Snapclarity was named as a defendant to an action commenced in the Ontario Superior Court of Justice by a former shareholder of Snapclarity and companies such shareholder purports to control (the "Plaintiff") (the "Action"). The nature of the Action involves various intellectual property, wrongful dismissal, unpaid invoices, defamation, and other related issues raised by the Plaintiff. The Plaintiff seeks payment of at least \$928 plus costs and interest as well as non-monetary relief. Snapclarity disputes the claim in its entirety. The Company is of the view that its defenses to the claims will prevail without liability to the Company; however, an estimate of the liability to the Company should the Plaintiff's claims succeed is \$150 and therefore an accrual for that amount as a contingent liability has been recorded.

On December 21, 2020, Snapclarity was named as a respondent to an application commenced in the Ontario Superior Court of Justice by a former shareholder of Snapclarity (the "Applicant") (the "Application"). In the Application, the Applicant purports to exercise the Applicant's her dissent rights under s. 190(5) of the CBCA. The Applicant also seeks an order fixing the fair value of the Applicant's shares in Snapclarity and requiring Snapclarity to pay the value of the shares together with costs and interest. The Applicant has claimed that the fair value of the Applicant's shares totals at least \$1,850. Snapclarity disputes this claim. On February 23, 2021, Snapclarity filed a Notice of Motion for an order converting the Application into an Action and consolidating the actions. The Applicant has not responded to the Notice of Motion as of this date.

In the Action, Snapclarity sought an injunction enjoining the former shareholder from, among other things, competing against Snapclarity. The injunction was not granted and Snapclarity must pay costs of \$150 to the former shareholder as a result.

19. SUBSEQUENT EVENT

On November 14, 2021, the Company entered into the Arrangement Agreement with MindBeacon pursuant to which the Company agreed to acquire all of MindBeacon's issued and outstanding common shares. MindBeacon is one of North America's leading clinically-validated internet-based cognitive behavioural therapy ("iCBT") solutions. Under the terms of the Arrangement Agreement, each common share of MindBeacon will be exchanged for \$1.22 cash and 2.285 common shares of CloudMD, with the total consideration expected to be up to approximately \$29,683 in cash and up to approximately 55.59 million common shares of CloudMD. Closing of the transaction is subject to a number of customary closing conditions, including approval by at least two-thirds of the votes cast at a special meeting of MindBeacon's shareholders, as well as court and regulatory approval. The MindBeacon shareholder meeting is expected to be held on or about January 10, 2022 and, subject to the satisfaction or waiver of the other closing conditions, closing is expected to occur shortly thereafter, on or about January 14, 2022.